The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...
The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start ...